Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announced that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx' nitric oxide technology. CLC-1280 is based on an established late lifecy more
To use all functions of this page, please activate cookies in your browser.